Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 22

1.

A UK audit of screening for the metabolic side effects of antipsychotics in community patients.

Barnes TR, Paton C, Cavanagh MR, Hancock E, Taylor DM; UK Prescribing Observatory for Mental Health.

Schizophr Bull. 2007 Nov;33(6):1397-403. Epub 2007 May 4.

2.

Metabolic monitoring for patients treated with antipsychotic medications.

Cohn TA, Sernyak MJ.

Can J Psychiatry. 2006 Jul;51(8):492-501. Review.

PMID:
16933586
3.

Guideline concordant monitoring of metabolic risk in people treated with antipsychotic medication: systematic review and meta-analysis of screening practices.

Mitchell AJ, Delaffon V, Vancampfort D, Correll CU, De Hert M.

Psychol Med. 2012 Jan;42(1):125-47. doi: 10.1017/S003329171100105X. Epub 2011 Aug 10. Review.

PMID:
21846426
4.

[Schizophrenia, diabetes mellitus and antipsychotics].

Gury C.

Encephale. 2004 Jul-Aug;30(4):382-91. Review. French.

PMID:
15538314
5.

Prolactin-related and metabolic adverse effects of atypical antipsychotic agents.

Henderson DC, Doraiswamy PM.

J Clin Psychiatry. 2008;69 Suppl 1:32-44. Review.

6.

Metabolic and endocrine disturbances in psychiatric disorders: a multidisciplinary approach to appropriate atypical antipsychotic utilization.

Masand PS, Culpepper L, Henderson D, Lee S, Littrell K, Newcomer JW, Rasgon N.

CNS Spectr. 2005 Oct;10(10):suppl14 1-15.

PMID:
16404802
7.

The comorbidity of diabetes mellitus and psychiatric disorders.

Medved V, Jovanović N, Knapić VP.

Psychiatr Danub. 2009 Dec;21(4):585-8. Review.

8.

Atypical antipsychotics and glucose homeostasis.

Bergman RN, Ader M.

J Clin Psychiatry. 2005 Apr;66(4):504-14. Review.

PMID:
15816794
9.

[Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].

Llorca PM, Miadi-Fargier H, Lançon C, Jasso Mosqueda G, Casadebaig F, Philippe A, Guillon P, Mehnert A, Omnès LF, Chicoye A, Durand-Zaleski I.

Encephale. 2005 Mar-Apr;31(2):235-46. Review. French.

PMID:
15959450
10.

Using antipsychotic agents in older patients.

Alexopoulos GS, Streim J, Carpenter D, Docherty JP; Expert Consensus Panel for Using Antipsychotic Drugs in Older Patients.

J Clin Psychiatry. 2004;65 Suppl 2:5-99; discussion 100-102; quiz 103-4. Review.

11.

Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of schizophrenia and related disorders.

Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines Team for the Treatment of Schizophrenia and Related Disorders.

Aust N Z J Psychiatry. 2005 Jan-Feb;39(1-2):1-30. Review.

PMID:
15660702
12.

Screening for type 2 diabetes: literature review and economic modelling.

Waugh N, Scotland G, McNamee P, Gillett M, Brennan A, Goyder E, Williams R, John A.

Health Technol Assess. 2007 May;11(17):iii-iv, ix-xi, 1-125. Review.

13.

Atypical antipsychotic drugs, schizophrenia, and metabolic syndrome in non-Euro-American societies.

Bou Khalil R.

Clin Neuropharmacol. 2012 May-Jun;35(3):141-7. doi: 10.1097/WNF.0b013e31824d5288. Review.

PMID:
22592510
14.

Screening for type 2 diabetes: a short report for the National Screening Committee.

Waugh NR, Shyangdan D, Taylor-Phillips S, Suri G, Hall B.

Health Technol Assess. 2013 Aug;17(35):1-90. doi: 10.3310/hta17350. Review.

15.

Metabolic syndrome and mental illness.

Newcomer JW.

Am J Manag Care. 2007 Nov;13(7 Suppl):S170-7. Review. Erratum in: Am J Manag Care. 2008 Feb;14(2):76.

16.

Weight gain and changes in metabolic variables following olanzapine treatment in schizophrenia and bipolar disorder.

Citrome L, Holt RI, Walker DJ, Hoffmann VP.

Clin Drug Investig. 2011;31(7):455-82. doi: 10.2165/11589060-000000000-00000. Review.

PMID:
21495734
17.

[Metabolic syndrome in patients with schizophrenia independently from atypical antipsychotics intake].

Bou Khalil R.

Presse Med. 2012 May;41(5):e238-43. doi: 10.1016/j.lpm.2011.10.013. Epub 2011 Dec 6. Review. French.

PMID:
22154487
18.

Screening for the metabolic syndrome in patients receiving antipsychotic treatment: a proposed algorithm.

Waterreus AJ, Laugharne JD.

Med J Aust. 2009 Feb 16;190(4):185-9. Review.

PMID:
19220182
19.

Minimising metabolic and cardiovascular risk in schizophrenia: diabetes, obesity and dyslipidaemia.

Barnett AH, Mackin P, Chaudhry I, Farooqi A, Gadsby R, Heald A, Hill J, Millar H, Peveler R, Rees A, Singh V, Taylor D, Vora J, Jones PB.

J Psychopharmacol. 2007 Jun;21(4):357-73. Review. Erratum in: J Psychopharmacol. 2008 Aug;22(6):699.

PMID:
17656425
20.

Management of schizophrenia with obesity, metabolic, and endocrinological disorders.

Monteleone P, Martiadis V, Maj M.

Psychiatr Clin North Am. 2009 Dec;32(4):775-94. doi: 10.1016/j.psc.2009.08.003. Review.

PMID:
19944883

Supplemental Content

Support Center